Sacubitril/Valsartan: potential treatment for paediatric heart failure

Bibhuti B. Das, Frank Scholl, Breanna Vandale, Maryanne Chrisant

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


The Prospective comparison of angiotensin receptor antagonist Valsartan and neprilysin inhibitor Sacubitril with angiotensin-converting enzyme inhibitor (enalapril) to determine impact on Global Mortality and Morbidity in Heart Failure trial has demonstrated that Sacubitril/Valsartan is superior to Enalapril in reducing the risks of both sudden cardiac death and death from worsening heart failure. This novel combination, Sacubitril/Valsartan, is also shown to reduce the risk of hospitalisation and progression of heart failure in adults. However, the benefit of Sacubitril/Valsartan in paediatric heart failure patients is unknown. In this review, we discuss the similarities and differences in pathophysiology of heart failure in children versus adults, and the potential role of Sacubitril/Valsartan in paediatric heart failure patients.

Original languageEnglish (US)
Pages (from-to)1-5
Number of pages5
JournalCardiology in the Young
StateAccepted/In press - Jul 6 2018


  • angiotensin receptor blocker
  • neprilysin inhibitor
  • Paediatric heart failure

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Sacubitril/Valsartan: potential treatment for paediatric heart failure'. Together they form a unique fingerprint.

Cite this